miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression.

Breast cancer is the most common type of malignancy in women, which remains a significant health concern worldwide. Gemcitabine is a frequently applied anticancer pharmacological agent. However, the efficacy of gemcitabine is limited by chemoresistance.